INTRODUCTION
Interleukin (IL)-4-targeted therapies have revolutionized management of inflammatory dermatoses. Dupilumab, an IL-4 receptor alpha inhibitor, is approved for moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis1 with ongoing studies including in urticaria, prurigo nodularis, and alopecia.2 Interleukins are critical mediators of immunosurveillance, and a theoretical increased risk of malignancy exists for any interleukin inhibitor until real-world long-term safety data are explored. Genomic expression studies can help examine if interleukin deficiencies are associated with increased malignancy risk, providing a proxy for long-term interleukin repression.
We utilize data from the Cancer Genome Atlas to investigate if IL-4 expression is correlated with overall survival (OS) in
![](https://s3.amazonaws.com/dl.jddonline.com/articleimages/23_4_L7941e+MEROLA/Expression-of-IL-4-in-Tumors----A-Safety-Surrogate-to-Predict-Cancer-Survival--Associated-With-Biologic-Therapies_Table1.png)